It was found that fibroblast growth factor 19 levels, known to have a protective effect on atherosclerosis in patients with type 2 diabetes, are down-regulated by OSA, thus weakening their protective effect and exacerbating outcomes, consistent with prior research (39, 40). This evidence concerns the gene FGF19 and atherosclerosis.